(Q24244900)

2

object named as

Ngamwong Jarusuraisin

0 references

Michael Soyka

6

object named as

Michael Soyka

0 references

author name string

Manit Srisurapanont

1

0 references

Susanne Rösner

1

0 references

Andrea Hackl-Herrwerth

2

0 references

Stefan Leucht

3

0 references

Simona Vecchi

4

0 references

Manit Srisurapanont

5

0 references

M Srisurapanont

1

0 references

N Jarusuraisin

Cochrane Database of Systematic Reviews

2

0 references

language of work or name

English

0 references

publication date

24 January 2005

0 references

8 December 2010

0 references

25 January 2005

0 references

published in

0 references

page(s)

CD001867

0 references

issue

12

0 references

1

0 references

cites work

Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Effects of naltrexone on cue-elicited craving for alcohol and cocaine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Using naltrexone in inpatient alcoholism treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Six-month follow-up of naltrexone and psychotherapy for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Tolerability of naltrexone in treating older, alcohol-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone improves outcome of a controlled drinking program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone increases the latency to drink alcohol in social drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Effects of naltrexone on alcohol self-administration in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Outpatient cognitive behavioural therapy programme for alcohol dependence: impact of naltrexone use on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

The effects of naltrexone on alcohol and cocaine use in dually addicted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Predictors of compliance with naltrexone among alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Pharmacological treatment of alcohol dependence: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Rating the quality of evidence for clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Endogenous opioid systems and alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Prophylactic treatment of alcoholism by lithium carbonate. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Modulation of ethanol-intake by morphine: evidence for a central site of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Pharmacologic Interventions for Alcohol- and Cocaine-Abusing Individuals: A Pilot Study of Disulfiram vs. Naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Naltrexone treatment of comorbid alcohol and cocaine use disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Alcohol drinking in rats during and following morphine injections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Naltrexone as an adjunctive treatment for older patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB2

7 January 2021

10.1002/14651858.CD001867.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_jfkz7fu5azbflmvy6sifhkbx3e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jfkz7fu5azbflmvy6sifhkbx3e

24 November 2022